FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ribavirin (REBETOL) USP Capsules
Status: Discontinuation
»Therapeutic Categories: Antiviral

Expand all

Merck Sharp & Dohme Corp. (New 09/23/2015)

Company Contact Information:
800-672-6372

Presentation Posting Date Related Information
REBETOL (ribavirin USP) capsules, for oral use, 200 mg; A bottle containing 56 capsules of REBETOL 200 mg (NDC 00085-1351-05) 09/23/2015 For business reasons, Merck is voluntarily discontinuing the manufacture and distribution of REBETOL in the United States, effective February 1, 2016.
REBETOL (ribavirin USP) capsules, for oral use, 200 mg; A bottle containing 70 capsules of REBETOL 200 mg (NDC 00085-1385-07) 09/23/2015 For business reasons, Merck is voluntarily discontinuing the manufacture and distribution of REBETOL in the United States, effective February 1, 2016.
REBETOL (ribavirin USP) capsules, for oral use, 200 mg; A bottle containing 84 capsules of REBETOL 200 mg (NDC 00085-1194-03) 09/23/2015 For business reasons, Merck is voluntarily discontinuing the manufacture and distribution of REBETOL in the United States, effective February 1, 2016.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English